Purpose: Delayed ferumoxytol enhancement on T 1 -weighted images appears visually similar to gadoteridol enhancement. The purpose of this study was to quantitatively compare ferumoxytol T 1 enhancement to gadoteridol enhancement with an objective, semi-automated method. Methods: 206 sets of post-gadoteridol and 24 h post-ferumoxytol T 1 -weighted scans from 58 high grade glioma patients were analyzed (9 pre-chemoradiation, 111 < 90 days post-chemoradiation, 21 > 90 days post-chemoradiation, 65 post-bevacizumab scans). Enhancement volumes and signal intensities normalized to normal appearing tissue proximal to enhancement were calculated with a semi-automated method. Enhancement cube root volumes (D) and signal intensities (SI) were compared between the 2 contrast agents, and relative difference of D and SI were compared in different treatment groups with multivariate analysis. Within patient differences in D and SI before and after treatment with bevacizumab or steroid were assessed in 26 patients in each treatment group. Results: When compared to gadoteridol, ferumoxytol D was 13.83% smaller and SI was 7.24% lower (P < 0.0001). The relative differences in D and SI between the 2 contrast agents were not significantly different between treatment groups (P > 0.05). Relative difference in D and SI did not change significantly in response to bevacizumab (P ¼ 0.5234 and P ¼ 0.2442, respectively) or to steroid (P ¼ 0.3774, P ¼ 0.0741) in the within patient comparison. Conclusion: The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy suggest that ferumoxytol can be used for revealing enhancement in high grade glioma patients.
INTRODUCTION
There is a current paucity of literature regarding the equivalence of enhancement for gadolinium-based contrast agents (GBCA) and non-GBCAs. Gadolinium-enhanced MRI is the standard of care for imaging various central nervous system pathologies. Over 10 million doses of GBCA are administered annually in the United States (1). Concerns regarding gadolinium safety (nephrogenic systemic fibrosis or gadolinium deposition in basal ganglia, of which the clinical significance of the latter is still unknown) (2-6) draw attention to the need for alternatives such as manganese-and iron-based contrast agents (7) (8) (9) .
Ferumoxytol is an ultra small superparamagnetic iron oxide nanoparticle that has been approved by the Food and Drug Administration for iron replacement therapy. Previous studies have shown its use as an MRI contrast agent when used off-label (10) . Whereas GBCAs leak into the brain parenchyma in areas where the blood-brain barrier is not intact several seconds after administration, ferumoxytol predominately remains intravascular for hours because of its high molecular weight, enabling excellent vascular visualization. Parenchymal enhancement peaks $24 h after administration (11) . Delayed phase ferumoxytol enhancement is manifested by T 1 shortening on spin echo MRI, making its appearance similar to GBCA enhancement. However, it is still unknown how delayed ferumoxytol enhancement differs from standard of care in visualizing central nervous system pathologies and monitoring changes related to disease.
The goals of this study were to (1) quantitatively compare ferumoxytol and gadoteridol T 1 enhancement magnitude and size with an objective, semiautomatic method in a large study population, and (2) to examine whether ferumoxytol enhancement changes similarly to gadoteridol enhancement in response to specific treatment regimens.
METHODS

Subjects
Between September 2009 and April 2015, 138 brain tumor patients were scanned prospectively in our institutional review board-approved, HIPAA-compliant protocol (https:// clinicaltrials.gov/ct2/show/NCT00103038). All subjects gave informed consent.
Inclusion criteria for this analysis included post-surgical, histologically proved high grade gliomas (World Health Organization classification grades III and IV), with both ferumoxytol and gadoteridol scans available. Initially, 221 sets of MR scans (221 post-gadoteridol and 221 post-ferumoxytol) of 61 patients met the inclusion criteria, but 16 sets of scans were excluded because of unsatisfactory image quality. Therefore, a total of 58 patients (37 males, 21 females, mean age 6 SD 51.32 6 13.25 years, 40 glioblastoma, 1 gliosarcoma, 6 anaplastic astrocytoma, 9 anaplastic oligodendroglioma, 2 anaplastic oligoastrocytoma) with 205 sets of MR scans from up to 6 available visits remained in the study. MR visits were stratified based on treatment received before each scan (pre-chemoradiation: 9 scans; within 90 d post-chemoradiation: 111 scans; > 90 d from chemoradiation: 21 scans; post-bevacizumab [Avastin, Genentech, South San Francisco, CA]: 64 scans). Steroid administration before scan was also recorded (yes or no).
MRI
All MRI scans were performed on a 3T clinical scanner (TIM Trio, Siemens, Erlangen Germany) using a 12-channel receive-only head coil. Pre-contrast, post-gadoteridol, and 24 h post-ferumoxytol T 1 -weighted scans were acquired using the same spin echo sequence with the following parameters: pulse repetition time (TR)/echo time (TE): 900/ 11 ms, flip angle 90 , field of view 180 Â 240 mm, matrix 192 Â 256, 44 axial slices, slice thickness 2 mm with no gap. Ferumoxytol was given in a 4 mg/kg dose. Ferumoxytol was diluted 1:1 with saline, resulting in 15 mg/mL concentration. Gadoteridol was administered using the 0.1 mmol/kg standard dose. Ferumoxytol was injected after performing post-gadoteridol scans, and delayed ferumoxytol scans were obtained $24 h after administration (mean 6 SD: 23.10 6 2.51 h).
Image Analysis
Image analysis was performed by 2 experts (D.S. and A.H.) with 12 and 6 years of experience and a radiologist (C.V.) with 10 years of experience in image processing. Post-gadoteridol and post-ferumoxytol images were coregistered to pre-contrast scans (6 degrees of freedom linear fit, correlation ratio cost function, and trilinear interpolation) using the FMRIB Software Library (FSL) Linear Image Registration Tool (FLIRT) (12) . Enhancing tumors were segmented using a semi-automated method. First, the same manually drawn region of interest (ROI) was applied on pre-contrast, post-gadoteridol, and postferumoxytol scans in FSL (13) . The ROI was drawn to cover all voxels that visually appeared to be enhancing for either co-registered contrast enhanced scan in all slices and also included normal appearing white and grey matter proximal to the enhancing volume (Figs. 1a, 1b , and 1d).
The final mask denoting contrast enhancement was the intersection of 3 independently derived binary masks, A\B\C, such that:
and B i Q; [2] and
where i is a voxel, CON is a contrast enhanced T 1 -weighted volume, NONCON is a non-contrast enhanced T 1 -weighted volume, Q is the manually drawn mask, s iQ is the standard deviation of a contrast-enhanced image within the manually drawn mask, and where denotes the proper subset. Put simply, for a voxel to be included in the final mask representing contrast enhancement, (1) it must have an contrast-enhanced intensity value that is larger than the sum of the mean contrast-enhanced intensity value and half of the standard deviation of the values within the manually drawn mask, (2) it must be a member of the manually drawn mask, and (3) the value of the quotient of contrast-enhanced and non-contrast-enhanced must be larger than the quotient of the sum of the mean contrast-enhanced intensity value and half of the standard deviation of the values within the manually drawn mask and the mean non-contrastenhanced intensity value within the manually drawn mask.
The standard deviation term in criteria 1 and 3 serves to adjust the threshold value (greater than the mean intensity) for manually drawn regions that contain more heterogeneous tissue samples. Because the order of tissue intensity on contrast-enhanced T 1 -weighted imaging generally follows (enhancement > white matter > gray matter > cerebrospinal fluid), any inclusion of tissue that is not enhancement will adjust the mean tissue intensity value downward inside the manual mask. However, just as the mean value is adjusted downward with the inclusion of non-enhancing tissue, the variance in the sample is adjusted upward, and so a modest correction using half of the standard deviation of the intensity values in the sample serves to make the threshold more conservative with respect to contrast enhanced values relative to non-contrast enhanced volumes.
Enhancement volumes were calculated for both contrast agents by multiplying the voxel counts in each mask by the voxel volume. As the distribution of absolute volumes of enhancement for both gadolinium and ferumoxytol was very positively skewed (many relatively small volumes and relatively fewer larger volumes), the cube root was taken for all volume measurements (referred to hereafter as "D") to more accurately represent a normal distribution for the purpose of statistical testing.
Enhancement signal intensities were normalized to the signal intensity value of non-enhancing voxels inside the manual ROI (the relative complement of the final mask in Q, i.e., Q n [A \ B \ C]); normalized signal intensity values are referred to as "SI".
Statistical Analysis
The primary outcomes were enhancement volumes and signal intensity. To satisfy the assumption of normal distribution, the cube root of volumes (D) was used in all analyses. Because of the lack of uniformity in lesion sizes among subjects, relative differences (not absolute differences) in D (i.e., were used to reduce possible impact of lesion size on the results (e.g., a large lesion may lead to a large difference between gadoteridol and ferumoxytol because the lesion size is larger, instead of because of the relative differential enhancement between gadoteridol and ferumoxytol). Pearson's correlation was used to assess the relationship between ferumoxytol and gadoteridol enhancement cube root volumes (D Fe and D Gd ) and signal intensities (SI Fe and SI Gd ). Overall comparison of ferumoxytol and gadoteridol enhancement was made in a random effects model while accounting for correlation among the repeated measures with the same patient.
A linear mixed effect model was used to compare relative difference of D Fe and D Gd and relative difference of SI Fe and SI Gd among different treatment groups while accounting for repeated measures and adjusting for potential confounding variables (time to scan after ferumoxytol injection, previous radiation, steroid treatment, age at visit and gender).
Additionally, within-subject relative difference of D Fe and D Gd and of SI Fe and SI Gd were compared in patients before and after bevacizumab (N ¼ 26), and in patients before and after steroid (N ¼ 26) with a linear mixed effect model. A P-value < 0.05 was considered statistically significant in all analyses. Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC). 
RESULTS
Overall Comparison of Contrast Enhancement
There was a strong correlation in enhancement cube root volumes (r ¼ 0.7979, P < 0.0001) and in signal intensities (r ¼ 0.5362, P < 0.0001) between the 2 contrast agents (Fig. 3) .
Overall, cube root of enhancement volumes were 3.00 mm or 13.83% lower with ferumoxytol than with gadoteridol (P < 0.0001) ( Fig. 4a; Table 1 ). Enhancement signal intensity was 7.24% lower with ferumoxytol than with gadoteridol (P < 0.0001) ( Fig. 4b; Table 1 ).
Comparison of Enhancement among Treatment Groups
The relative differences of D and SI between contrast agents were not statistically significantly different among the 4 different treatment groups after adjusting for patient characteristics (D, P ¼ 0.7905 and SI, P ¼ 0.3725) ( Figs. 4c and 4d ; Table 1 ).
Within-Subject Comparison of Enhancement
Relative difference between contrast agents did not change significantly in response to bevacizumab (cube root volume: before bevacizumab vs. after bevacizumab 3.6%, P ¼ 0.5234; signal intensity: before bevacizumab vs. after bevacizumab À1.5%, P ¼ 0.2442) (Figs. 4e and 4f; Table 1 ).
Similarly, results for within-subject assessment in response to steroid were not significantly different for cube root volumes (before vs. after steroid, 5.28%, P ¼ 0.3774), or signal intensity (before vs. after steroid, 2.9%, P ¼ 0.0741) ( Figs. 4g and 4h ; Table 1 ).
DISCUSSION
The apparent visual similarity between gadoteridol and delayed ferumoxytol T 1 enhancement (14) raises the question whether ferumoxytol could be a feasible option for diagnosing central nervous system pathologies. The use of ferumoxytol as an alternative contrast agent in the future is predicated on a complete understanding of how ferumoxytol enhancement behaves and how it differs from standard of care gadoteridol enhancement. Therefore, this study aimed to compare ferumoxytol and gadoteridol T 1 enhancement in a standardized, unbiased, quantitative way in a large number of scans. For the overall cohort, ferumoxytol enhancement size was smaller and signal intensity was lower with the current imaging settings compared to those of gadoteridol. When stratified by treatment groups, the difference between contrast agents was not significant, although the sample size was smaller in this analysis. The longitudinal aspect of the study revealed unchanged relative differences between contrast agents in response to bevacizumab and steroid (i.e., when gadoteridol enhancement changed, ferumoxytol enhancement followed it).
To interpret the clinical significance of these results appropriately, it is important to understand what factors affect contrast enhancement. Enhancement size and signal intensity depend on the pathology, the relaxivity of the contrast agent, B 0 field strength, the sequence parameters, the injected contrast agent dose, the timing of the scan after contrast agent administration, and the difference in enhancement mechanism between contrast agents (10, 11, 15) . In this study, the 2 contrast agents were compared in the same pathologies on 3T field strength using the same sequence parameters. The rest of the listed factors were different between contrast agents. Specifically, longitudinal relaxivity of Feridex, an agent similar to ferumoxytol, is lower (2.7 mM À1 s À1 ) than that of gadoteridol (3.7 mM À1 s À1 ) in plasma at 37 C on 3T (15) that results in a lower signal intensity on a T 1 scan performed with the same sequence parameters (longitudinal relaxivity of ferumoxytol at 3T is currently unavailable). On the other hand, at lower field strength (1.5T), longitudinal relaxivity of ferumoxytol (15.1 mM À1 s À1 ) is favorable compared to gadoteridol (6.0 mM À1 s À1 ) (16). In our experience, by increasing ferumoxytol dose, enhancement signal intensity normalized to white matter increases, and relative difference in signal intensities between ferumoxytol and gadoteridol T 1 enhancement becomes smaller (unpublished data). Enhancement dynamics of ferumoxytol and gadoteridol are different due in part to their different molecular sizes (30 nm vs. 1 nm median displacement size, respectively) (10, 17) . Specifically, gadoteridol has a 0.2 h distribution and 1.6 h elimination half-life with peak enhancement in the brain parenchyma appearing 10 min after injection (18) . On the other hand, plasma elimination half-life of ferumoxytol is 14.7 h with enhancement in the parenchyma peaking 24 h post-administration (19) . Ferumoxytol enhancement size increases over time even 70 h after injection, whereas signal intensity peaks between 24 and 48 h after injection (11) . In addition, although gadoteridol is extracellular after extravasation, ferumoxytol can be present both intra-and extracellularly (20) .
Based on this information, differences in enhancement size and signal intensity in this study may have originated from inequivalent timing or dosing of ferumoxytol compared to gadoteridol. Using a higher ferumoxytol dose at lower field strength and adjusting the timing of the scan after injection might alter delayed ferumoxytol enhancement size and signal intensity. Determining the optimal dose and timing for delayed ferumoxytol scan is out of the scope of this study, although results were linearly adjusted for time between injection and delayed ferumoxytol scan in the statistical analysis. Instead, this study compared delayed enhancement to standard of care post-contrast images with a commonly used ferumoxytol dose and the typical 24 h post-injection scan timing. The difference in enhancement mechanism between gadoteridol and ferumoxytol suggests that changes in blood-brain barrier permeability (i.e., after treatment with bevacizumab or steroid) would affect enhancement with the 2 contrast agents differently. Despite this, the relative differences between contrast agents were not significantly different before and after treatment. One possibility for this null finding is that, given enough time post-injection, both contrast agents will extravasate if the blood-brain barrier is disrupted. If ferumoxytol enhancement immediately postinjection were being assessed in this report, instead of $24 h after administration, we would expect a larger differential effect of bevacizumab or steroids on the resultant T 1 enhancement of GBCA relative to ferumoxytol. It is important to note that in this investigation, both GBCA and delayed ferumoxytol enhancement volumes decreased after the commencement of bevacizumab treatment.
These results are similar to the findings of Hamilton et al. (14) and D osa et al. (21) who also measured slightly decreased enhancement size and signal intensity with ferumoxytol compared to gadoteridol. However, these studies included patients with various pathologies (i.e., the patient group was inhomogeneous), the ROIs were defined manually, and different ferumoxytol doses were used. In the study by Hamilton et al. (14) , lesion size was measured on 1 axial slice. In the present study, a greater number of cases were evaluated, volumetry was performed, and only high grade glioma patients were included, which resulted in a more homogeneous patient group. Our method was semi-automated to decrease subjectivity. Furthermore, the longitudinal aspect of our study enabled follow up of contrast enhancement changes over time in the same patient.
An important clinical question is whether it has a clinical impact if ferumoxytol enhancement size and signal intensity are slightly different of that of GBCA and what degree of difference between contrast agents are acceptable in the clinical setting. If there is only a slight difference in enhancement size and signal intensity between contrast agents, and the clinical question is tumor location and morphology, this difference might not affect the actual clinical diagnosis. However, if the question is whether a lesion has grown or a disease has progressed, it is important to use the same contrast agent for follow up that was used as baseline to be able to precisely differentiate progression from stable disease.
In contrast, unique properties of an additional contrast agent can provide an added value to standard of care. Specifically, ferumoxytol provides improved vascular visualization on T Ã 2 -weighted scans (11) and can be used to obtain high resolution cerebral blood volume maps for more accurate neurosurgical targeting (22) . Because of its greater transverse relaxivity, ferumoxytol shows delayed hypointense susceptibility on T 2 -weighted scans in the brain parenchyma in patients with increased blood-brain barrier permeability. Hypointense T 2 -weighted signal is generally not available in the time frame of minutes to hours after GBCA administration because of the rapid washout phase of the smaller agent relative to ferumoxytol (14) . The occasional mismatch in T 1 enhancement pattern between gadoteridol and ferumoxytol might provide additional information on tumor pathology and is currently being investigated. Ferumoxytol is a feasible alternative MR contrast agent in renally compromised patients. Iron is an essential element in the body, and the iron core of ferumoxytol incorporates into natural iron stores, therefore, the concern of toxicity because of deposition is low in people without iron storage diseases (23) (24) (25) (26) .
A limitation of this study is that, relative to the overall comparison, the smaller sample sizes for between treatment comparisons and within patient comparisons in response to bevacizumab or steroid limits the power to detect a meaningful difference. Another limitation is that in the within patient comparison, the time between the pre-and post-treatment scans was different in every patient; however, the comparison of ferumoxytol and gadoteridol was performed within the same study visit. In addition, because this is a clinical study, patients may have received other therapies besides steroid and bevacizumab that could have affected the results of the within patient comparison.
In conclusion, objectively comparing delayed ferumoxytol enhancement to current standard of care and assessing the ability of ferumoxytol to detect and monitor changes related to diseases are important steps toward developing ferumoxytol as an additional MR imaging agent. The correlation between the 2 contrast agents' enhancement size and signal intensity and their similar behavior in response to therapy is promising; however, the clinical impact of timing and dosing of ferumoxytol for delayed imaging needs to be further assessed.
